Is a Surprise Coming for IDEAYA Biosciences (IDYA) This Earnings Season?Zacks Investment Research • 08/07/20
IDEAYA Announces HSR Clearance of GSK Strategic Partnership in Synthetic Lethality and Closing of Glaxo Group Equity InvestmentPRNewsWire • 08/04/20
IDEAYA Announces IDE196 Program Update and Clinical Protocol Criteria Met for Cohort Expansion in Skin Melanoma for Phase 2 GNAQ/11 Basket TrialPRNewsWire • 07/16/20
IDEAYA to Participate in Fireside Chat at BTIG Biotechnology Conference and Wedbush PacGrow Healthcare Conference on August 11 and 12, 2020PRNewsWire • 07/14/20
IDEAYA Biosciences Doses First Patient in a Phase 1 Combination Study of IDE196 and Binimetinib, a MEK InhibitorPRNewsWire • 07/09/20
IDEAYA Appoints Garret Hampton, Ph.D., to the Board of Directors, an Industry Leader in Precision Medicine Oncology and DiagnosticsPRNewsWire • 06/30/20
IDEAYA and GSK Announce a Broad Partnership in Synthetic Lethality, an Emerging Field in Precision Medicine OncologyPRNewsWire • 06/16/20
IDEAYA Announces Nomination of Development Candidate, IDE397, for MAT2A Synthetic Lethality Program Targeting MTAP-Deletion Patient PopulationPRNewsWire • 06/08/20
IDEAYA Biosciences to Participate in Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020PRNewsWire • 05/19/20
IDEAYA Biosciences Announces AACR Abstracts for IDE196 Targeting GNAQ/11 Tumors and Preclinical MAT2A Synthetic Lethality ProgramPRNewsWire • 05/15/20